Chief Executive Officer

Mr. Léon J.A. Spijkers, PhD

Cofounded Korecyte Bio in 2023. Leon has over 15 years’ experience in Life Sciences and Pharma management, R&D and business development. Léon founded a biotech interim-management and consultancy firm via which he held several client positions as Chief Business Officer and BD Director positions. He worked with biotech start-ups up to multinational company clients, co-founded a clinical-stage drug-delivery company and accumulated a significant track record in evolving ventures to the next phase. He holds a PhD in molecular cell biology, is a registered pharmacologist and holds a certificate in business administration from the London School of Economics.

Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies
Chief Scientific Officer

Dr James N. Arnold, DPhil

Cofounded Korecyte Bio in 2023. James has over 20 years of research experience in the field of Immunology. He acquired his DPhil at the University of Oxford and conducted his Postdoctoral research at the University of Cambridge. James established the Tumour Immunology Group at King’s College London in 2012 and has dedicated his team there to developing new immunotherapy strategies for treating cancer. James has sat on Grant Committees for major UK cancer charities and currently holds the academic grade of Reader in Tumour Immunology and Immunotherapy at King’s College London. James is a co-inventor of HypoxiCAR Immunotherapy.

Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies

Interested in Korecyte Bio? Contact us or read more about our scientific approach.